New triple therapy targets lung tumors in bone cancer patients
NCT ID NCT06492954
First seen Dec 26, 2025 · Last updated May 20, 2026 · Updated 22 times
Summary
This early-phase study is for people whose osteosarcoma has come back in the lungs. It combines an immunotherapy drug (atezolizumab) with precise radiation and surgery to remove tumors. The main goal is to see if this approach is safe and tolerable, with a secondary focus on controlling the disease for at least 12 months. About 12 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chilldren's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.